Prothena Biosciences Ltd. and Vanderbilt University have jointly discovered dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of Alzheimer’s disease, cancer, diabetes, cardiovascular disorders and Down syndrome.
Researchers from Prothena Biosciences Ltd. recently presented preclinical data for the full effector-function IgG1 monoclonal antibody PRX-012, which binds with high affinity to both soluble and insoluble forms of toxic amyloid-β (Aβ) aggregates.
Prothena Biosciences Ltd. has developed dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors reported to be useful for the treatment of Alzheimer’s disease.
